Breast tumor PDXs are genetically plastic and correspond to a subset of aggressive cancers prone to relapse

Molecular Oncology

Volumn 8, Issue 2, 2014, Pages 431-443

  du Manoir, Stanislas ^a   Orsetti, Béatrice ^a,b   Bras Gonçalves, Rui ^a,b   Nguyen, Tien Tuan ^a   Lasorsa, Laurence ^a,b   Boissière, Florence ^b   Massemin, Blandine ^b   Colombo, Pierre Emmanuel ^a,b   Bibeau, Frédéric ^b   Jacot, William ^a,b   Theillet, Charles ^a,b  

^a INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTPELLIER   (France)

^b CENTRE VAL D AURELLE   (France)

Author keywords

Adverse prognosis; Breast cancer; Genetic stability; Patient derived xenografts

Indexed keywords

ARTICLE; BREAST TUMOR; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL FEATURE; FEMALE; GENETIC STABILITY; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PATIENT DERIVED XENOGRAFT; PRIMARY TUMOR; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; TRIPLE NEGATIVE BREAST CANCER; TUMOR XENOGRAFT; BREAST CANCER; COPY NUMBER CHANGE; GENE DOSAGE; HISTOPATHOLOGY; PHENOTYPE;

ADVERSE PROGNOSIS; BREAST CANCER; GENETIC STABILITY; PATIENT DERIVED XENOGRAFTS;

ANIMALS; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; TRANSCRIPTOME;

ESTROGEN RECEPTOR;

EID: 84894305985     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2013.11.010     Document Type: Article

References (30)

1. Banerji S., Cibulskis K., Rangel-Escareno C., Brown K.K., Carter S.L., Frederick A.M., Lawrence M.S., Sivachenko A.Y., Sougnez C., Zou L., Cortes M.L., Fernandez-Lopez J.C., Peng S., Ardlie K.G., Auclair D., Bautista-Piña V., Duke F., Francis J., Jung J., Maffuz-Aziz A., Onofrio R.C., Parkin M., Pho N.H., Quintanar-Jurado V., Ramos A.H., Rebollar-Vega R., Rodriguez-Cuevas S., Romero-Cordoba S.L., Schumacher S.E., Stransky N., Thompson K.M., Uribe-Figueroa L., Baselga J., Beroukhim R., Polyak K., Sgroi D.C., Richardson A.L., Jimenez-Sanchez G., Lander E.S., Gabriel S.B., Garraway L.A., Golub T.R., Melendez-Zajgla J., Toker A., Getz G., Hidalgo-Miranda A., Meyerson M. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012, 486:405-409.
2. Bergamaschi A., Hjortland G.O., Triulzi T., Sørlie T., Johnsen H., Ree A.H., Russnes H.G., Tronnes S., Maelandsmo G.M., Fodstad O., Borresen-Dale A.-L., Engebraaten O. Molecular profiling and characterization of luminal-like and basal-like invivo breast cancer xenograft models. Mol. Oncol. 2009, 3:469-482.
3. Chang H.Y., Sneddon J.B., Alizadeh A.A., Sood R., West R.B., Montgomery K., Chi J.-T., van de Rijn M., Botstein D., Brown P.O. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol. 2004, 2:E7.
4. Cutz J.C., Guan J., Bayani J., Yoshimoto M., Xue H., Sutcliffe M., English J., Flint J., LeRiche J., Yee J., Squire J.A., Gout P.W., Lam S., Wang Y.Z. Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes. Clin. Cancer Res. 2006, 12:4043-4054.
5. DeRose Y.S., Wang G., Lin Y.-C., Bernard P.S., Buys S.S., Ebbert M.T.W., Factor R., Matsen C., Milash B.A., Nelson E., Neumayer L., Randall R.L., Stijleman I.J., Welm B.E., Welm A.L. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat. Med. 2011, 17:1514-1520.
6. Dhakal H.P., Naume B., Synnestvedt M., Borgen E., Kaaresen R., Schlichting E., Wiedswang G., Bassarova A., Holm R., Giercksky K.-E., Nesland J.M. Expression of vascular endothelial growth factor and vascular endothelial growth factor receptors 1 and 2 in invasive breast carcinoma: prognostic significance and relationship with markers for aggressiveness. Histopathology 2012, 61:350-364.
7. Fernando R.I., Castillo M.D., Litzinger M., Hamilton D.H., Palena C. IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells. Cancer Res. 2011, 71:5296-5306.
8. Fiebig H.H., Maier A., Burger A.M. Clonogenic assay with established human tumour xenografts: correlation of invitro to invivo activity as a basis for anticancer drug discovery. Eur. J. Cancer 2004, 40:802-820.
9. Gasparini G. Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist 2000, 5(Suppl. 1):37-44.
10. Ginestier C., Liu S., Diebel M.E., Korkaya H., Luo M., Brown M., Wicinski J., Cabaud O., Charafe-Jauffret E., Birnbaum D., Guan J.-L., Dontu G., Wicha M.S. CXCR1 blockade selectively targets human breast cancer stem cells invitro and in xenografts. J.Clin. Invest. 2010, 120:485-497.
11. Gnirke A., Melnikov A., Maguire J., Rogov P., LeProust E.M., Brockman W., Fennell T., Giannoukos G., Fisher S., Russ C., Gabriel S., Jaffe D.B., Lander E.S., Nusbaum C. Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat. Biotechnol. 2009, 27:182-189.
12. Guedj M., Marisa L., de Reynies A., Orsetti B., Schiappa R., Bibeau F., Macgrogan G., Lerebours F., Finetti P., Longy M., Bertheau P., Bertrand F., Bonnet F., Martin A.L., Feugeas J.P., Bièche I., Lehmann-Che J., Lidereau R., Birnbaum D., Bertucci F., de Thé H., Theillet C. A refined molecular taxonomy of breast cancer. Oncogene 2012, 31:1196-1206.
13. Hait W.N. Anticancer drug development: the grand challenges. Nat. Rev. Drug Discov. 2010, 9:253-254.
14. Hartman Z.C., Poage G.M., Hollander, den P., Tsimelzon A., Hill J., Panupinthu N., Zhang Y., Mazumdar A., Hilsenbeck S.G., Mills G.B., Brown P.H. Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Res. 2013, 73:3470-3480.
15. Hu Z., Fan C., Livasy C., He X., Oh D.S., Ewend M.G., Carey L.A., Subramanian S., West R., Ikpatt F., Olopade O.I., van de Rijn M., Perou C.M. A compact VEGF signature associated with distant metastases and poor outcomes. BMC Med. 2009, 7:9.
16. Kao J., Salari K., Bocanegra M., Choi Y.-L., Girard L., Gandhi J., Kwei K.A., Hernandez-Boussard T., Wang P., Gazdar A.F., Minna J.D., Pollack J.R. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS ONE 2009, 4:e6146.
17. Koboldt D.C., Fulton R.S., McLellan M.D., Schmidt H., Kalicki-Veizer J., Mcmichael J.F., Fulton L.L., Dooling D.J., Ding L., Mardis E.R., Wilson R.K., Ally A., Balasundaram M., Butterfield Y.S.N., Carlsen R., Carter C., Chu A., Chuah E., Chun H.-J.E., Coope R.J.N., Dhalla N., Guin R., Hirst C., Hirst M., Holt R.A., Lee D., Li H.I., Mayo M., Moore R.A., Mungall A.J., Pleasance E., Gordon Robertson A., Schein J.E., Shafiei A., Sipahimalani P., Slobodan J.R., Stoll D., Tam A., Thiessen N., Varhol R.J., Wye N., Zeng T., Zhao Y., Birol I., Jones S.J.M., Marra M.A., Cherniack A.D., Saksena G., Onofrio R.C., Pho N.H., Carter S.L., Schumacher S.E., Tabak B., Hernandez B., Gentry J., Nguyen H., Crenshaw A., Ardlie K., Beroukhim R., Winckler W., Getz G., Gabriel S.B., Meyerson M., Chin L., Park P.J., Kucherlapati R., Hoadley K.A., Todd Auman J., Fan C., Turman Y.J., Shi Y., Li L., Topal M.D., He X., Chao H.-H., Prat A., Silva G.O., Iglesia M.D., Zhao W., Usary J., Berg J.S., Adams M., Booker J., Wu J., Gulabani A., Bodenheimer T., Hoyle A.P., Simons J.V., Soloway M.G., Mose L.E., Jefferys S.R., Balu S., Parker J.S., Neil Hayes D., Perou C.M., Malik S., Mahurkar S., Shen H., Weisenberger D.J., Triche T., Lai P.H., Bootwalla M.S., Maglinte D.T., Berman B.P., Van Den Berg D.J., Baylin S.B., Laird P.W., Creighton C.J., Donehower L.A., Getz G., Noble M., Voet D., Saksena G., Gehlenborg N., DiCara D., Zhang J., Zhang H., Wu C.-J., Yingchun Liu S., Lawrence M.S., Zou L., Sivachenko A., Lin P., Stojanov P., Jing R., Cho J., Sinha R., Park R.W., Nazaire M.-D., Robinson J., Thorvaldsdottir H., Mesirov J., Park P.J., Chin L., Reynolds S., Kreisberg R.B., Bernard B., Bressler R., Erkkila T., Lin J., Thorsson V., Zhang W., Shmulevich I., Ciriello G., Weinhold N., Schultz N., Gao J., Cerami E., Gross B., Jacobsen A., Sinha R., Arman Aksoy B., Antipin Y., Reva B., Shen R., Taylor B.S., Ladanyi M., Sander C., Anur P., Spellman P.T., Lu Y., Liu W., Verhaak R.R.G., Mills G.B., Akbani R., Zhang N., Broom B.M., Casasent T.D., Wakefield C., Unruh A.K., Baggerly K., Coombes K., Weinstein J.N., Haussler D., Benz C.C., Stuart J.M., Benz S.C., Zhu J., Szeto C.C., Scott G.K., Yau C., Paull E.O., Carlin D., Wong C., Sokolov A., Thusberg J., Mooney S., Ng S., Goldstein T.C., Ellrott K., Grifford M., Wilks C., Ma S., Craft B., Yan C., Hu Y., Meerzaman D., Gastier-Foster J.M., Bowen J., Ramirez N.C., Black A.D., Pyatt R.E., White P., Zmuda E.J., Frick J., Lichtenberg T.M., Brookens R., George M.M., Gerken M.A., Harper H.A., Leraas K.M., Wise L.J., Tabler T.R., McAllister C., Barr T., Hart-Kothari M., Tarvin K., Saller C., Sandusky G., Mitchell C., Iacocca M.V., Brown J., Rabeno B., Czerwinski C., Petrelli N., Dolzhansky O., Abramov M., Voronina O., Potapova O., Marks J.R., Suchorska W.M., Murawa D., Kycler W., Ibbs M., Korski K., Spychała A., Murawa P., Brzeziński J.J., Perz H., Łaźniak R., Teresiak M., Tatka H., Leporowska E., Bogusz-Czerniewicz M., Malicki J., Mackiewicz A., Wiznerowicz M., Van Le X., Kohl B., Viet Tien N., Thorp R., Van Bang N., Sussman H., Duc Phu B., Hajek R., Phi Hung N., Viet The Phuong T., Quyet Thang H., Zaki Khan K., Penny R., Mallery D., Curley E., Shelton C., Yena P., Ingle J.N., Couch F.J., Lingle W.L., King T.A., Maria Gonzalez-Angulo A., Mills G.B., Dyer M.D., Liu S., Meng X., Patangan M., Waldman F., Stöppler H., Kimryn Rathmell W., Thorne L., Huang M., Boice L., Hill A., Morrison C., Gaudioso C., Bshara W., Daily K., Egea S.C., Pegram M.D., Gomez-Fernandez C., Dhir R., Bhargava R., Brufsky A., Shriver C.D., Hooke J.A., Leigh Campbell J., Mural R.J., Hu H., Somiari S., Larson C., Deyarmin B., Kvecher L., Kovatich A.J., Ellis M.J., King T.A., Hu H., Couch F.J., Mural R.J., Stricker T., White K., Olopade O., Ingle J.N., Luo C., Chen Y., Marks J.R., Waldman F., Wiznerowicz M., Bose R., Chang L.-W., Beck A.H., Maria Gonzalez-Angulo A., Pihl T., Jensen M., Sfeir R., Kahn A., Chu A., Kothiyal P., Wang Z., Snyder E., Pontius J., Ayala B., Backus M., Walton J., Baboud J., Berton D., Nicholls M., Srinivasan D., Raman R., Girshik S., Kigonya P., Alonso S., Sanbhadti R., Barletta S., Pot D., Sheth M., Demchok J.A., Mills Shaw K.R., Yang L., Eley G., Ferguson M.L., Tarnuzzer R.W., Zhang J., Dillon L.A.L., Buetow K., Fielding P., Ozenberger B.A., Guyer M.S., Sofia H.J., Palchik J.D. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70.
18. Landis M.D., Lehmann B.D., Pietenpol J.A., Chang J.C. Patient-derived breast tumor xenografts facilitating personalized cancer therapy. Breast Cancer Res. 2013, 15:201.
19. Marangoni E., Vincent-Salomon A., Auger N., Degeorges A., Assayag F., de Cremoux P., de Plater L., Guyader C., De Pinieux G., Judde J.G., Rebucci M., Tran-Perennou C., Sastre-Garau X., Sigal-Zafrani B., Delattre O., Dieras V., Poupon M.-F. A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin. Cancer Res. 2007, 13:3989-3998.
20. Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., Clark L., Bayani N., Coppe J.-P., Tong F., Speed T., Spellman P.T., DeVries S., Lapuk A., Wang N.J., Kuo W.-L., Stilwell J.L., Pinkel D., Albertson D.G., Waldman F.M., McCormick F., Dickson R.B., Johnson M.D., Lippman M., Ethier S., Gazdar A., Gray J.W. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10:515-527.
21. Nik-Zainal S., Van Loo P., Wedge D.C., Alexandrov L.B., Greenman C.D., Lau K.W., Raine K., Jones D., Marshall J., Ramakrishna M., Shlien A., Cooke S.L., Hinton J., Menzies A., Stebbings L.A., Leroy C., Jia M., Rance R., Mudie L.J., Gamble S.J., Stephens P.J., Mclaren S., Tarpey P.S., Papaemmanuil E., Davies H.R., Varela I., McBride D.J., Bignell G.R., Leung K., Butler A.P., Teague J.W., Martin S., Jönsson G., Mariani O., Boyault S., Miron P., Fatima A., Langerød A., Aparicio S.A.J.R., Tutt A., Sieuwerts A.M., Borg A., Thomas G., Salomon A.V., Richardson A.L., Børresen-Dale A.-L., Futreal P.A., Stratton M.R., Campbell P.J., Breast Cancer Working Group of the International Cancer Genome Consortium The life history of 21 breast cancers. Cell 2012, 149:994-1007.
22. Nugoli M., Chuchana P., Vendrell J., Orsetti B., Ursule L., Nguyen C., Birnbaum D., Douzery E.J.P., Cohen P., Theillet C. Genetic variability in MCF-7 sublines: evidence of rapid genomic and RNA expression profile modifications. BMC Cancer 2003, 3:13.
23. Petrillo L.A., Wolf D.M., Kapoun A.M., Wang N.J., Barczak A., Xiao Y., Korkaya H., Baehner F., Lewicki J., Wicha M.S., Spellman P.T., Gray J.W., van't Veer L.J., Esserman L.J. Xenografts faithfully recapitulate breast cancer-specific gene expression patterns of parent primary breast tumors. Breast Cancer Res. Treat. 2012, 135:913-922.
24. Quintana E., Shackleton M., Sabel M.S., Fullen D.R., Johnson T.M., Morrison S.J. Efficient tumour formation by single human melanoma cells. Nature 2008, 456:593-598.
25. Reyal F., Guyader C., Decraene C., Lucchesi C., Auger N., Assayag F., De Plater L., Gentien D., Poupon M.-F., Cottu P., de Cremoux P., Gestraud P., Vincent-Salomon A., Fontaine J.-J., Roman-Roman S., Delattre O., Decaudin D., Marangoni E. Molecular profiling of patient-derived breast cancer xenografts. Breast Cancer Res. 2012, 14:R11.
26. Rody A., Karn T., Liedtke C., Pusztai L., Ruckhaeberle E., Hanker L., Gaetje R., Solbach C., Ahr A., Metzler D., Schmidt M., Müller V., Holtrich U., Kaufmann M. A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res. 2011, 13:R97.
27. Singh J.K., Farnie G., Bundred N.J., Simoes B.M., Shergill A., Landberg G., Howell S.J., Clarke R.B. Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and - Independent mechanisms. Clin. Cancer Res. 2013, 19:643-656.
28. Sotiriou C., Wirapati P., Loi S., Harris A., Fox S., Smeds J., Nordgren H., Farmer P., Praz V., Haibe-Kains B., Desmedt C., Larsimont D., Cardoso F., Peterse H., Nuyten D., Buyse M., van de Vijver M.J., Bergh J., Piccart M., Delorenzi M. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J.Natl. Cancer Inst. 2006, 98:262-272.
29. Waugh D.J.J., Wilson C. The interleukin-8 pathway in cancer. Clin. Cancer Res. 2008, 14:6735-6741.
30. Zhang X., Claerhout S., Prat A., Dobrolecki L., Petrovic I., Lai Q., Landis M., Wiechmann L., Schiff R., Giuliano M., Wong H., Fuqua S., Contreras A., Gutierrez C., Huang J., Mao S., Pavlick A., Froehlich A.M., Wu M.F., Tsimelzon A., Hilsenbeck S.G., Chen E., Zuloaga P., Shaw C., Rimawi M.F., Perou C.M., Mills G.B., Chang J.C., Lewis M.T. A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenografts. Cancer Res. 2013, 73:4885-4897.